Ann: Appendix 4C - quarterly, page-14

The big issue is that it's become almost impossible for AHZ to raise any more money. No one is stupid enough at this stage to buy into another CR, and no one will lend them any more except at loanshark rates. So outside of actual revenue, the taps are well and truly all shut. I think this is probably the first time that AHZ has been in this position. Up until now, there have always been greater fools to tap. The only thing that can save them now is a mutually beneficial partnership with an actual medical industry partner. Not another under the table deal with dodgy VC or vultures looking for a bargain.